Editorial: ADAMTS13 and thrombotic thrombocytopenic purpura: Where we are and where we need to go

Transfusion

Volumn 50, Issue 8, 2010, Pages 1640-1642

  Raife, Homas J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

BLOOD TRANSFUSION; EDITORIAL; ENZYME ACTIVITY; HUMAN; PATHOGENESIS; PLASMAPHERESIS; PROTEIN DEFICIENCY; THROMBOCYTE ADHESION; THROMBOTIC THROMBOCYTOPENIC PURPURA; NOTE; PHYSIOLOGY;

ADAM PROTEINS; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 77955162708     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02778.x     Document Type: Editorial

References (14)

1. Bentley MJ, Lehman CM, Blaylock RC, Wilson AR, Rodgers GM. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion 2010 50 : 1654 64.
2. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987 32 : 292 308.
3. George J, Vesely S, Rizvi M. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. In : Coleman RW, editor. Hemostasis and thrombosis. Philadelphia (PA) : Lippincott Williams & Wilkins 2001. p. 1235 42.
4. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003 1 : 625 31.
5. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002 100 : 710 3. (Pubitemid 34761143)
6. Raife T, Atkinson B, Montgomery RR, Vesely S, Friedman KD. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004 44 : 146 50.
7. Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N, Mannucci PM Italian Registry Of Recurrent And Familial HUS/TTP. Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002 100 : 778 85.
8. Kelton JG. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment? (Editorial). Tranfusion 2002 42 : 388 92.
9. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004 103 : 4043 9.
10. Moore J, Hayward C, Warkentin T, Kelton J. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001 98 : 1842 6.
11. Vesely S, George J, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003 102 : 60 8.
12. Friedman K, Raife T, Endres J, Pietz B. Correlations between ADAMTS13 activity and inhibitor levels: observations and implications for resource utilization. J Thromb Haemost 2007 5 Suppl 2 : P-M-291.
13. Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010 115 : 1500 11.
14. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005 19 : 2 31.